NASDAQ:SNDX - Syndax Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$7.36 +0.01 (+0.14 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$7.35
Today's Range$7.32 - $7.61
52-Week Range$6.61 - $15.20
Volume198,642 shs
Average Volume363,686 shs
Market Capitalization$180.60 million
P/E Ratio-2.53
Dividend YieldN/A
Beta1.25

Headlines

Syndax Pharmaceuticals (NASDAQ SNDX) News Headlines

Source:
DateHeadline
Syndax Pharmaceuticals Inc (SNDX) Receives Average Rating of "Buy" from AnalystsSyndax Pharmaceuticals Inc (SNDX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 14 at 3:22 PM
HC Wainwright Initiates Coverage on Syndax Pharmaceuticals (SNDX)HC Wainwright Initiates Coverage on Syndax Pharmaceuticals (SNDX)
www.americanbankingnews.com - July 12 at 7:46 AM
 Brokerages Anticipate Syndax Pharmaceuticals Inc (SNDX) to Announce -$0.94 EPS Brokerages Anticipate Syndax Pharmaceuticals Inc (SNDX) to Announce -$0.94 EPS
www.americanbankingnews.com - June 30 at 4:18 AM
Syndax Pharmaceuticals Inc (SNDX) Short Interest Up 59.6% in JuneSyndax Pharmaceuticals Inc (SNDX) Short Interest Up 59.6% in June
www.americanbankingnews.com - June 28 at 2:30 AM
Syndax Pharmaceuticals Inc (SNDX) Given Average Rating of "Buy" by BrokeragesSyndax Pharmaceuticals Inc (SNDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 18 at 5:32 AM
Zacks: Analysts Expect Syndax Pharmaceuticals Inc (SNDX) to Announce -$0.94 Earnings Per ShareZacks: Analysts Expect Syndax Pharmaceuticals Inc (SNDX) to Announce -$0.94 Earnings Per Share
www.americanbankingnews.com - June 12 at 9:30 PM
Global Ocular Cancer Drug Development Pipeline Review 2018: 35 Products in Active Development Featuring ...Global Ocular Cancer Drug Development Pipeline Review 2018: 35 Products in Active Development Featuring ...
www.prnewswire.com - June 12 at 8:57 AM
Mining ASCO 2018s Gold, Part 7: Digest This News And Get Valuable InformationMining ASCO 2018's Gold, Part 7: Digest This News And Get Valuable Information
seekingalpha.com - May 31 at 9:19 AM
Syndax Pharmaceuticals, Nektar to Study NKTR-214 in Patients with PD-1 Refractory MelanomaSyndax Pharmaceuticals, Nektar to Study NKTR-214 in Patients with PD-1 Refractory Melanoma
www.nasdaq.com - May 31 at 9:19 AM
Syndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanomaSyndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanoma
seekingalpha.com - May 31 at 9:19 AM
Syndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 TrialSyndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 Trial
seekingalpha.com - May 28 at 10:05 AM
 Brokerages Anticipate Syndax Pharmaceuticals Inc. (SNDX) Will Post Earnings of -$0.94 Per Share Brokerages Anticipate Syndax Pharmaceuticals Inc. (SNDX) Will Post Earnings of -$0.94 Per Share
www.americanbankingnews.com - May 26 at 10:40 AM
Syndax Pharmaceuticals Inc. (SNDX) Given Average Rating of "Buy" by BrokeragesSyndax Pharmaceuticals Inc. (SNDX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 5:31 AM
Syndax: One Step Backward, Two Forward?Syndax: One Step Backward, Two Forward?
seekingalpha.com - May 23 at 4:40 PM
A Requested Update On SyndaxA Requested Update On Syndax
seekingalpha.com - May 23 at 8:49 AM
Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Time?Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Time?
seekingalpha.com - May 21 at 9:18 AM
Blog Exposure - Syndax Pharma Shares Results of Phase-2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDABlog Exposure - Syndax Pharma Shares Results of Phase-2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA
finance.yahoo.com - May 21 at 9:18 AM
Syndax Pharmaceuticals: What Investors Can Expect From This Potential Grower?Syndax Pharmaceuticals: What Investors Can Expect From This Potential Grower?
seekingalpha.com - May 18 at 4:43 PM
Syndax Pharmaceuticals (SNDX) Rating Lowered to Sell at ValuEngineSyndax Pharmaceuticals (SNDX) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - May 17 at 10:23 PM
Syndax down 22% on mid-stage entinostat dataSyndax down 22% on mid-stage entinostat data
seekingalpha.com - May 17 at 4:40 PM
Syndax Pharmaceuticals Presents Updated Phase 2 Cancer-Drug Test ResultsSyndax Pharmaceuticals Presents Updated Phase 2 Cancer-Drug Test Results
www.nasdaq.com - May 17 at 9:21 AM
Syndax (SNDX) Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDASyndax (SNDX) Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA
www.streetinsider.com - May 17 at 9:21 AM
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)
finance.yahoo.com - May 17 at 9:21 AM
Zacks Investment Research Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"Zacks Investment Research Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"
www.americanbankingnews.com - May 15 at 2:09 PM
Syndax Pharmaceuticals Inc. Forecasted to Post Q2 2018 Earnings of ($0.83) Per Share (SNDX)Syndax Pharmaceuticals Inc. Forecasted to Post Q2 2018 Earnings of ($0.83) Per Share (SNDX)
www.americanbankingnews.com - May 14 at 1:40 AM
Oppenheimer Weighs in on Syndax Pharmaceuticals Inc.s Q2 2018 Earnings (SNDX)Oppenheimer Weighs in on Syndax Pharmaceuticals Inc.'s Q2 2018 Earnings (SNDX)
www.americanbankingnews.com - May 14 at 1:40 AM
Syndax Pharmaceuticals: Is This A Multi-Bagger In The Making?Syndax Pharmaceuticals: Is This A Multi-Bagger In The Making?
seekingalpha.com - May 13 at 4:49 PM
Edited Transcript of SNDX earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of SNDX earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:27 AM
Syndax Pharmaceuticals (SNDX) Rating Lowered to Sell at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:23 PM
Syndax Pharmaceuticals (SNDX) Issues Quarterly  Earnings ResultsSyndax Pharmaceuticals (SNDX) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 2:38 PM
Syndax Pharmaceuticals beats by $0.17, misses on revenueSyndax Pharmaceuticals beats by $0.17, misses on revenue
seekingalpha.com - May 9 at 9:14 AM
Syndax Pharmaceuticals (SNDX) CEO Briggs Morrison on Q1 2018 Results - Earnings Call TranscriptSyndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:14 AM
Syndax: 1Q Earnings SnapshotSyndax: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:14 AM
Syndax Pharmaceuticals Inc (SNDX) Expected to Announce Earnings of -$1.02 Per ShareSyndax Pharmaceuticals Inc (SNDX) Expected to Announce Earnings of -$1.02 Per Share
www.americanbankingnews.com - May 9 at 3:10 AM
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - May 8 at 4:44 PM
Syndax Pharmaceuticals (SNDX) Upgraded to Hold by ValuEngineSyndax Pharmaceuticals (SNDX) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 2 at 6:12 PM
Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018
finance.yahoo.com - May 1 at 9:07 AM
Syndax Pharmaceuticals (SNDX) Scheduled to Post Quarterly Earnings on MondaySyndax Pharmaceuticals (SNDX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 8:17 AM
Syndax Pharmaceuticals Inc (SNDX) Given Average Recommendation of "Buy" by AnalystsSyndax Pharmaceuticals Inc (SNDX) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 5:30 AM
Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual MeetingSyndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - April 25 at 4:41 PM
Syndax to Present at the 2018 American Association for Cancer Research Annual MeetingSyndax to Present at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 21 at 9:02 AM
ValuEngine Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"ValuEngine Upgrades Syndax Pharmaceuticals (SNDX) to "Hold"
www.americanbankingnews.com - April 20 at 12:45 PM
Syndax Pharmaceuticals (SNDX) Downgraded by ValuEngineSyndax Pharmaceuticals (SNDX) Downgraded by ValuEngine
www.americanbankingnews.com - April 17 at 10:55 PM
Syndax Pharmaceuticals (SNDX) Downgraded to "D" at TheStreetSyndax Pharmaceuticals (SNDX) Downgraded to "D" at TheStreet
www.americanbankingnews.com - April 17 at 8:17 AM
Syndax Pharmaceuticals Inc (SNDX) Sees Large Drop in Short InterestSyndax Pharmaceuticals Inc (SNDX) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 15 at 1:14 AM
Technical Perspectives on Biotech Stocks -- Syndax Pharma, Teligent ...Technical Perspectives on Biotech Stocks -- Syndax Pharma, Teligent ...
www.prnewswire.com - April 11 at 4:39 PM
Syndax Pharmaceuticals (SNDX) Downgraded by BidaskClubSyndax Pharmaceuticals (SNDX) Downgraded by BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM
Syndax Pharmaceuticals (SNDX) Downgraded by Zacks Investment Research to "Hold"Syndax Pharmaceuticals (SNDX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 6 at 10:54 PM
Peter Ordentlich Sells 7,500 Shares of Syndax Pharmaceuticals Inc (SNDX) StockPeter Ordentlich Sells 7,500 Shares of Syndax Pharmaceuticals Inc (SNDX) Stock
www.americanbankingnews.com - April 3 at 10:46 PM
Syndax Pharmaceuticals (SNDX) Lifted to "Buy" at Zacks Investment ResearchSyndax Pharmaceuticals (SNDX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:48 PM
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.